ATE189856T1 - Auf membran-gebundenem, nicht aber auf sezerniertem iga vorkommende antigene epitope - Google Patents

Auf membran-gebundenem, nicht aber auf sezerniertem iga vorkommende antigene epitope

Info

Publication number
ATE189856T1
ATE189856T1 AT90909984T AT90909984T ATE189856T1 AT E189856 T1 ATE189856 T1 AT E189856T1 AT 90909984 T AT90909984 T AT 90909984T AT 90909984 T AT90909984 T AT 90909984T AT E189856 T1 ATE189856 T1 AT E189856T1
Authority
AT
Austria
Prior art keywords
membrane
secreted iga
bond
antigen epitopes
occurring
Prior art date
Application number
AT90909984T
Other languages
English (en)
Inventor
Tse Wen Chang
Nancy T Chang
Original Assignee
Tanox Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/369,479 external-priority patent/US5079344A/en
Application filed by Tanox Biosystems Inc filed Critical Tanox Biosystems Inc
Application granted granted Critical
Publication of ATE189856T1 publication Critical patent/ATE189856T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT90909984T 1989-06-21 1990-06-21 Auf membran-gebundenem, nicht aber auf sezerniertem iga vorkommende antigene epitope ATE189856T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/369,479 US5079344A (en) 1989-06-21 1989-06-21 Antigenic epitopes present on membrane-bound but not secreted IgA
US07/455,080 US5089603A (en) 1989-06-21 1989-12-22 Antigenic epitopes present on membrane-bound but not secreted iga
PCT/US1990/003532 WO1990015614A1 (en) 1989-06-21 1990-06-21 ANTIGENIC EPITOPES PRESENT ON MEMBRANE-BOUND BUT NOT SECRETED IgA

Publications (1)

Publication Number Publication Date
ATE189856T1 true ATE189856T1 (de) 2000-03-15

Family

ID=27004597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90909984T ATE189856T1 (de) 1989-06-21 1990-06-21 Auf membran-gebundenem, nicht aber auf sezerniertem iga vorkommende antigene epitope

Country Status (11)

Country Link
US (2) US5089603A (de)
EP (1) EP0478665B1 (de)
JP (1) JP2612512B2 (de)
AT (1) ATE189856T1 (de)
AU (1) AU645256B2 (de)
CA (1) CA2060666C (de)
DE (1) DE69033461T2 (de)
DK (1) DK0478665T3 (de)
ES (1) ES2142790T3 (de)
SG (1) SG52589A1 (de)
WO (1) WO1990015614A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514776A (en) * 1987-12-31 1996-05-07 Tanox Biosystems, Inc. Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface
US5362643A (en) * 1989-06-21 1994-11-08 Tanox Biosystems Antibodies to epitopes present on membrane-bound but not secreted IGA
US5266477A (en) * 1990-02-02 1993-11-30 Pitman-Moore, Inc. Monoclonal antibodies which differentiate between native and modified porcine somatotropins
US20100267023A1 (en) * 1992-09-24 2010-10-21 Keygene N.V. Selective restriction fragment amplification: fingerprinting
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
IT1315254B1 (it) * 1999-11-05 2003-02-03 Diesse Diagnostica Senese Spa Metodo per la determinazione qualitativa e quantitativa di anticorpiumani di classe igc.
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
UA93854C2 (ru) * 2003-12-17 2011-03-25 Вайет Ллк Иммуногенный конъюгат и способ его получения
EP1699810A4 (de) * 2003-12-17 2009-10-21 Elan Pharm Inc A beta-immunogene peptid-träger-konjugate und verfahren zu deren herstellung
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
PE20061329A1 (es) * 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
EP1941275B1 (de) 2005-09-29 2013-07-24 Medimmune, Inc. Verfahren zur identifizierung membran-lg-spezifischer antikörper und verwendung davon zur ansteuerung immunglobulin produzierender vorläuferzellen
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2146746A4 (de) * 2007-04-18 2011-03-23 Janssen Alzheimer Immunotherap Vorbeugung und behandlung von zerebraler amyloid-angiopathy
US20080283557A1 (en) * 2007-05-17 2008-11-20 Julianne Desautels Spout for food stuff container
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SG174161A1 (en) 2009-02-25 2011-11-28 Tsewen Chang ANTI-CemX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES
CN104603150A (zh) 2012-04-20 2015-05-06 中央研究院 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体
TWI603979B (zh) * 2013-12-05 2017-11-01 中央研究院 抗人類膜錨定型免疫球蛋白a抗體能夠溶解帶有膜錨定型免疫球蛋白a的b淋巴球與降低免疫球蛋白a 的生產
EP3703753A4 (de) 2017-10-31 2021-08-18 Oneness Biotech Co., Ltd. Behandlung von ige-vermittelten allergischen erkrankungen
US12497464B1 (en) 2018-08-03 2025-12-16 Berkeley Therapeutics, Inc. Antibody, antibody fragments or peptide for treating cancer and methods of formation and administration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE230883C (de) *
US4636463A (en) * 1984-04-05 1987-01-13 Scripps Clinic And Research Foundation Antibodies to human interleukin-2 induced by synthetic polypeptides
DE122006000007I2 (de) * 1987-12-31 2008-03-27 Tanox Inc -tragenden b-lymphocyten befinden.

Also Published As

Publication number Publication date
JP2612512B2 (ja) 1997-05-21
DK0478665T3 (da) 2000-07-24
US5089603A (en) 1992-02-18
JPH04504424A (ja) 1992-08-06
EP0478665A1 (de) 1992-04-08
WO1990015614A1 (en) 1990-12-27
US5866129A (en) 1999-02-02
EP0478665A4 (en) 1993-02-17
AU5854790A (en) 1991-01-08
AU645256B2 (en) 1994-01-13
SG52589A1 (en) 1998-09-28
DE69033461D1 (de) 2000-03-30
CA2060666A1 (en) 1990-12-22
EP0478665B1 (de) 2000-02-23
ES2142790T3 (es) 2000-05-01
DE69033461T2 (de) 2000-10-12
CA2060666C (en) 2001-07-10

Similar Documents

Publication Publication Date Title
DE69033461D1 (de) Auf membran-gebundenem, nicht aber auf sezerniertem iga vorkommende antigene epitope
NZ219113A (en) Hiv peptide containing epitope of the env protein
DK0555276T3 (da) Immunogene komplekser, især iscomer
HRP20020721B1 (en) Novel method for down-regulation of amyloid
DK0722340T3 (da) Immunologisk toleranceinducerende middel
DE3574730D1 (de) Monoklonaler antikoerper gegen ein humanes tumor-karzinom-assoziiertes antigen.
ATE377027T1 (de) Tetravalente antikörperkonstrukte
NO980293D0 (no) Fremgangsmåte til fremstilling av et polypeptid
DE69128273D1 (de) Für toxin b von clostridium difficile spezifische monoklonale antikörper
ES551496A0 (es) Procedimiento de obtencion de un anticuerpo monoclonal reactivo con antigenos de esporozoitos de eimeria spp.
ES2114064T3 (es) Inmunoanalisis para la deteccion de colageno o fragmentos de colageno.
ES551495A0 (es) Procedimiento de obtencion de un anticuerpo monoclonal reactivo con antigenos de esporozoitos o merozoitos de eimeria spp.
DE69327529D1 (de) Immunologisch mit HLA homologe HIV Protein Epitope
NO873774D0 (no) Monoklonale eller polyklonale antistoffer.
DE3585370D1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
ES2061664T3 (es) Anticuerpos monoclonales que reconocen a alfa-hanp y correspondientes hibridomas, su preparacion y uso.
DE3482813D1 (de) Adult t-zell-leukemiavirus-antigenpeptid.
DE69836024D1 (de) Pseudomonas exotoxin a-ähnliche chimerische immunogene zum auslösen einer sekretorischen iga-vermittelten immunantwort
ES2061973T3 (es) Anticuerpos monoclonales que reconocen la region n-terminal de polipeptido natriuretico auricular, su preparacion y uso.
FI934963A7 (fi) CTAA 81AV78, monoklonaalisen 81AV78-humaanivasta-aineen tunnistama ant igeeni
ATE28937T1 (de) Immunotest fuer kohlehydrat-antigen-determinant.
ES2058113T3 (es) Metodo de preparacion y uso de antigenos de virus de leucemia felina.
FI924576A7 (fi) CTAA 28A32, MCA 28A32:n tunnistama antigeeni
DK329789A (da) Monoklonalt antistof
ATE140233T1 (de) Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee